The UK National Screening Committee (UK NSC) is preparing to advise the government on expanding prostate cancer screening for men, a move that could establish a national, population-wide program.
Currently, the UK does not have routine screening despite advocacy from cancer organizations for broader testing, especially for high-risk groups.
The committee’s concerns center on the prostate-specific antigen (PSA) blood test, which has limitations in accuracy. PSA testing can miss treatable cancers and falsely identify cancer where none exists, leading to unnecessary interventions with significant side effects such as incontinence and erectile dysfunction.
General practitioners can currently offer PSA testing to men showing symptoms or men aged 50 and over, even without symptoms. The committee is considering broader testing scenarios, including targeted screening for men with family histories, ethnicities at higher risk, and carriers of BRCA2 gene mutations.
A major new trial called Transform, funded with £42 million, is investigating the effectiveness of combining PSA with MRI scans to improve early detection and reduce overdiagnosis and overtreatment.
Prostate cancer primarily affects men over 65, with black men facing double the risk and those with affected family members experiencing a 2-4 times higher chance of developing the disease. BRCA2 mutations also elevate the risk and lead to earlier diagnoses.
The Transform trial, now recruiting, aims to test whether a screening approach can reduce mortality while minimizing harm. The committee’s recommendation, expected soon, could mark a turning point in prostate cancer screening practice in the UK.
Related topics
